Literature DB >> 30607122

Appropriate treatment receipt after breast-conserving surgery.

K Guidolin1, M Lock2,3, K Vogt2,3, J A McClure4, J Winick-Ng4, C Vinden2,3,4, M Brackstone2,3.   

Abstract

Background: Breast-conserving surgery (bcs) and radiation therapy (rt) are the standard of care for early breast cancer, although some women receive ipsilateral mastectomy or adjuvant tamoxifen, both of which can be appropriate alternatives to rt. Objectives of the present study were to determine the proportion of women who are treated appropriately after bcs and to identify factors associated with non-receipt of rt.
Methods: This retrospective cohort study used Ontario data linked at the Institute for Clinical and Evaluative Sciences to examine 33,718 patients who received bcs during 2004-2010. Primary outcome was rt receipt. The ipsilateral mastectomy rate and patient, surgeon, and setting variables were measured.
Results: Of the study patients, 86.1% received either rt or completion mastectomy; in the cohort less than 70 years of age, 90.8% received rt or completion mastectomy. Among patients less than 70 years of age, 3 risk factors for non-receipt of rt were identified: age less than 46 years, treatment in a non-academic institution, and earlier year of initial bcs. Additionally, in the overall cohort, rt non-receipt was associated with high comorbidity, more than 40 km to the cancer centre, income quintile, and breast care specialization. Conclusions: In Ontario, 90.8% of patients less than 70 years of age are appropriately treated for early breast cancer; approximately 1 in 10 do not receive rt or completion mastectomy. Based on those findings, women less than 46 years of age might be at increased risk of recurrence and death because of incomplete treatment. It also appears that academic centres more effectively treat breast cancer; however, breast cancer care appears to be improving over time in Ontario.

Entities:  

Keywords:  Radiation; breast cancer; surgery

Mesh:

Year:  2018        PMID: 30607122      PMCID: PMC6291280          DOI: 10.3747/co.25.4117

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  23 in total

1.  Compliance differences between patients with breast cancer in university and county hospitals.

Authors:  Ian K Komenaka; Robert E Pennington; Bryan P Schneider; Chiu-Hsieh Hsu; Laura E Norton; Susan E Clare; Noelia M Zork; Robert J Goulet
Journal:  Clin Breast Cancer       Date:  2010-10-01       Impact factor: 3.225

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Adjuvant radiotherapy on older and oldest breast cancer patients after conservative surgery: a retrospective analysis.

Authors:  Francesco Fiorica; Massimiliano Berretta; Stefano Ursino; Rossella Fisichella; Arben Lleshi; Gerlando Fiorica; Antonio Stefanelli; Giampaolo Zini; Umberto Tirelli; Antonio Zanghi; Alessandro Cappellani; Salvatore Berretta; Francesco Cartei
Journal:  Arch Gerontol Geriatr       Date:  2011-10-28       Impact factor: 3.250

4.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

Authors:  J A van Dongen; A C Voogd; I S Fentiman; C Legrand; R J Sylvester; D Tong; E van der Schueren; P A Helle; K van Zijl; H Bartelink
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

5.  Factors contributing to underuse of radiation among younger women with breast cancer.

Authors:  I-Wen Pan; Benjamin D Smith; Ya-Chen Tina Shih
Journal:  J Natl Cancer Inst       Date:  2013-12-07       Impact factor: 13.506

6.  Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reporting.

Authors:  Titilayo O Adegboyega; Jeffrey Landercasper; Jared H Linebarger; Jeanne M Johnson; Jeremiah J Andersen; Leah L Dietrich; Collin D Driscoll; Meghana Raghavendra; Anusha R Madadi; Mohammed Al-Hamadani; Choua A Vang; Kristen A Marcou; Jane Hudak; Ronald S Go
Journal:  J Natl Compr Canc Netw       Date:  2015-02       Impact factor: 11.908

7.  Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.

Authors:  J A Jacobson; D N Danforth; K H Cowan; T d'Angelo; S M Steinberg; L Pierce; M E Lippman; A S Lichter; E Glatstein; P Okunieff
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

8.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.

Authors:  B Fisher; S Anderson; C K Redmond; N Wolmark; D L Wickerham; W M Cronin
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

9.  Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Authors:  Matthew M Poggi; David N Danforth; Linda C Sciuto; Sharon L Smith; Seth M Steinberg; David J Liewehr; Cynthia Menard; Marc E Lippman; Allen S Lichter; Rosemary M Altemus
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

10.  Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group.

Authors:  R Arriagada; M G Lê; F Rochard; G Contesso
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

View more
  1 in total

1.  Recurrence and mortality after breast-conserving surgery without radiation.

Authors:  K Guidolin; M Lock; K Vogt; J A McClure; J Winick-Ng; C Vinden; M Brackstone
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.